Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human KDM4C Antibodies:
anti-Mouse (Murine) KDM4C Antibodies:
anti-Rat (Rattus) KDM4C Antibodies:
Go to our pre-filtered search.
Human Polyclonal KDM4C Primary Antibody for ChIP, IP - ABIN258060
Ratovitski: Phospho-ΔNp63α/microRNA network modulates epigenetic regulatory enzymes in squamous cell carcinomas. in Cell cycle (Georgetown, Tex.) 2014
Show all 4 Pubmed References
Human Polyclonal KDM4C Primary Antibody for ChIP, ICC - ABIN4332082
Lee, Yang, Park: Hypoxia enhances the expression of prostate-specific antigen by modifying the quantity and catalytic activity of Jumonji C domain-containing histone demethylases. in Carcinogenesis 2013
Show all 4 Pubmed References
Cow (Bovine) Polyclonal KDM4C Primary Antibody for WB - ABIN2777688
Lu, Ward, Kapoor, Rohle, Turcan, Abdel-Wahab, Edwards, Khanin, Figueroa, Melnick, Wellen, ORourke, Berger, Chan, Levine, Mellinghoff, Thompson: IDH mutation impairs histone demethylation and results in a block to cell differentiation. in Nature 2012
Histone demethylases KDM3A, KDM4A, and KDM4C were expressed before and after embryonic genome activation, whereas KDM5B was mainly expressed during the blastocyst period.
CircZMYM2 repressed the expression of its target miR-335-5p. MiR-335-5p attenuated pancreatic cancer development via inhibition of JMJD2C.
we have identified KDM4C as a new risk gene shared between systemic vasculitides, consistent with the increasing evidences of the crucial role that the epigenetic mechanisms have in the development of complex immune-mediated conditions.
LSD1 and JMJD2C disable oncogenic Ras- or Braf-induced senescence by enabling the expression of E2F target genes
JMJD2C regulated the activities of lung cancer cells by directly controlling the expression of CUL4A in JMJD2C over-expression cell line.
histone H3 lysine 9 methylation reduction, which may be due to the downregulation of methyltransferase SUV39H2 and the upregulation of demethylase KDM4C, was found in CD4(+) T lymphocytes of Latent autoimmune diabetes in adult patients
KDM4C recognition of H3K4me3 stimulates demethylation of H3K9me3 in cis on peptide and mononucleosome substrates.
Pharmacological inhibition of KDM4C/PRMT1 suppresses transcription and transformation ability of MLL fusions
JMJD2B and JMJD2C play an important role in the pathology of osteosarcoma via the up-regulation of FGF2.
Data suggest that D396N polymorphism of JmjC domain-containing histone demethylase JMJD2C affects the prognosis of breast cancer by altering caspase-3 cleavage and the ability of double strand DNA break repair which may contribute to therapy resistance.
GASC1 expression is higher in adenocarcinoma than squamous cell carcinoma. Smoking decreases GASC1 expression in tumor cells, indicating that tobacco smoke may influence the methylation of histone 3 lysine residues in lung cancer.
KDM4C promotes transcriptional activation by removing the repressive histone mark, H3K9me3, from its target genes. Variation in its expression leads to differences in the growth of normal and some cancer cells.
KDM4C maintains the sphere-forming capacity in CRCs by mediating the beta-catenin-dependent transcription of JAG1 in a feed-forward manner.
analysis of the nickel-induced inhibition of truncated constructs of JMJD2A and JMJD2C histone demethylases using X-ray absorption spectroscopy
Patients with GASC1 positive tumors have better breast cancer specific survival and respond better to radiotherapy and hormonal treatment
JMJD2C decreases trimethylation of histone H3 at lysine 9, and enhances HIF-1 binding to hypoxia response elements, thereby activating transcription of proteins that are required for metabolic reprogramming and for lung metastasis.
JMJD2C displays an optimal activity in vitro at alphaKG concentrations similar to those found in cancer cells, with implications for the regulation of histone demethylation activity in cancer versus normal cells.
This study presented that KDM4C showed strong associations with alcohol withdrawal symptoms (p < 5 x 10-5).
inhibition measurements showed significant selectivity between KDM4C and KDM6A
The strongest association in obsessive-compulsive disorder has been found at rs301443 (P=0.000067) residing between SLC1A1 and JMJD2C at 9p24.
identification of genetic alterations & expression changes of LSD1, JHDM2A & GASC1 in prostate cancer (PC); as no genetic alterations & only modest expression changes were found, it is unlikely they play a major role in progression of PC
Jmjd2c and G9a are novel enhancer-associated factors; Jmjd2c is a molecular scaffold for the assembly of essential enhancer-protein complexes with an impact on timely gene activation
The authors show that Jmjd2a and Jmjd2c both localize to H3K4me3-positive promoters, where they have widespread and redundant roles in preventing accumulation of H3K9me3 and H3K36me3.
Number of GFAP-positive astrocytes in the brain of Gasc1 hypomorphic mutant mice is increased at 2-3 months of age.
GASC1 has an oncogenic role in mouse skin carcinogenesis.
These findings together demonstrate the essential role of KDM4A and KDM4C in orchestrating mESC differentiation to endothelial cells through the activation of Flk1 and VE-cadherin promoters, respectively
Jmjd2C increases MyoD transcriptional activity to facilitate skeletal muscle differentiation by increasing MyoD stability through inhibiting G9a-dependent MyoD degradation.
Jmjd2b unique, Jmjd2c unique, and Jmjd2b-Jmjd2c common target sites belong to functionally separable Core, Polycomb repressive complex (PRC), and Myc regulatory modules, respectively.
Inositol pyrophosphates regulate JMJD2C-dependent histone demethylation.
stage-specifically expressed during preimplantation development, with the highest activity being observed from the two-cell to the eight-cell stage
Jmjd2c acts as a positive regulator for Nanog, which encodes for a key transcription factor for self-renewal in ES cells.
These results indicate that Mdm2 oncogene is a downstream target of Jmjd2c and may play an important role in Jmjd2c-mediated oncogenesis.
This gene is a member of the Jumonji domain 2 (JMJD2) family and encodes a protein with one JmjC domain, one JmjN domain, two PHD-type zinc fingers, and two Tudor domains. This nuclear protein functions as a trimethylation-specific demethylase, converting specific trimethylated histone residues to the dimethylated form. Chromosomal aberrations and increased transcriptional expression of this gene are associated with esophageal squamous cell carcinoma. Alternative splicing results in multiple transcript variants.
jumonji domain containing 2C
, lysine (K)-specific demethylase 4C
, jumonji domain containing 2c
, lysine-specific demethylase 4C
, lysine-specific demethylase 4C-like
, GASC-1 protein
, JmjC domain-containing histone demethylation protein 3C
, gene amplified in squamous cell carcinoma 1 protein
, jumonji domain-containing protein 2C
, tudor domain containing 14C
, gene amplified in squamous cell carcinoma 1
, jmjC domain-containing histone demethylation protein 3C